Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Nat Med
    August 2025
  1. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
    Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
    Nat Med. 2025 Aug 26. doi: 10.1038/s41591-025-03975.
    >> Share

  2. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
    Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
    Nat Med. 2025 Aug 14. doi: 10.1038/s41591-025-03875.
    >> Share

  3. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
    Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
    Nat Med. 2025 Aug 4. doi: 10.1038/s41591-025-03896.
    >> Share

  4. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
    Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
    Nat Med. 2025 Aug 1. doi: 10.1038/s41591-025-03904.
    >> Share

  5. YAN S, Yu Z, Primiero C, Vico-Alonso C, et al
    A multimodal vision foundation model for clinical dermatology.
    Nat Med. 2025;31:2691-2702.
    >> Share

    July 2025
  6. MILOTAY G, Little M, Watson RA, Muldoon D, et al
    CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
    Nat Med. 2025;31:2350-2364.
    >> Share

  7. WERMKE M, Araujo DM, Chatterjee M, Tsimberidou AM, et al
    Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial.
    Nat Med. 2025;31:2365-2374.
    >> Share

    June 2025
  8. MONSON KR, Ferguson R, Handzlik JE, Morales L, et al
    Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
    Nat Med. 2025 Jun 5. doi: 10.1038/s41591-025-03699.
    >> Share

    May 2025
  9. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
    Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
    Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03715.
    >> Share

    January 2025
  10. DUMMER R, Robert C, Scolyer RA, Taube JM, et al
    Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
    Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03411.
    >> Share

  11. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
    Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03418.
    >> Share

    June 2024
  12. LONG GV, Carlino MS, Au-Yeung G, Spillane AJ, et al
    Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
    Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077.
    >> Share

  13. O'LEARY K
    Neoadjuvant immunotherapy a new standard of care for melanoma.
    Nat Med. 2024 Jun 17. doi: 10.1038/d41591-024-00045.
    >> Share

    February 2024
  14. BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al
    Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
    Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803.
    >> Share

    January 2024
  15. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    >> Share

  16. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775.
    >> Share

    November 2023
  17. FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al
    Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631.
    >> Share

  18. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650.
    >> Share

  19. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661.
    >> Share

    October 2023
  20. KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al
    Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583.
    >> Share

    August 2023
  21. VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al
    Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498.
    >> Share

  22. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    >> Share

  23. BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al
    A reinforcement learning model for AI-based decision support in skin cancer.
    Nat Med. 2023;29:1941-1946.
    >> Share

    July 2023
  24. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453.
    >> Share

  25. BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al
    Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
    Nat Med. 2023;29:1728-1737.
    >> Share

    May 2023
  26. GARBE C, Dummer R, Amaral T, Amaria RN, et al
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
    Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336.
    >> Share

    April 2023
  27. LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al
    Multi-organ landscape of therapy-resistant melanoma.
    Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304.
    >> Share

  28. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    >> Share

    March 2023
  29. O'LEARY K
    Earlier appears better for immunotherapy in melanoma.
    Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028.
    >> Share

  30. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    >> Share

    February 2023
  31. TIAN J, Chen JH, Chao SX, Pelka K, et al
    Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial.
    Nat Med. 2023;29:458-466.
    >> Share

  32. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016